If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
Traveling when you have idiopathic pulmonary fibrosis takes planning, but it’s doable. Experts share tips to help you stay ...
Idiopathic pulmonary fibrosis (IPF) is a serious lung condition involving scar tissue inside your lungs that makes it hard to breathe. It is a progressive condition, which means that it gets worse ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
San Francisco: The legendary tabla virtuoso, Ustad Zakir Hussain passed away on Monday in San Francisco at the age of 73. According to a statement from his family, Hussain's death was caused by ...
Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...
IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...
Early diagnosis and treatment in IPF and PPF are vital, as fibrosis is irreversible and current therapies only slow progression. Current IPF treatments, pirfenidone and nintedanib, have significant ...
Please provide your email address to receive an email when new articles are posted on . Rentosertib was shown to be safe in a 12-week phase 2a trial in China. Two doses improved FVC vs. placebo.
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Swigris: Before we ...